|
Board of Directors
Farmacule’s Board consists of a dedicated team with collective
experience in technology commercialisation, intellectual property
protection, capital raisings, government relations and financial
management.
The Board takes a strategic and hands-on approach to managing Farmacule
and the development and commercialisation of its core technology.
Mel Bridges
Chairman - Board of Directors
David Hudson Dip. Agri.Sci., Post Dip. Ag Extension,
Post Dip. Agribusiness
Chief Executive Officer and Director
Professor James Dale PhD
Chief Scientific Officer
Mark Xavier BA (Mil) MBA (Exec)
Director
Professor David Gardiner LLM
(Hons), LLB, BA
Director
Michael Finney MBA, B En (Hons), AICD
Director
Dr John Raff Dip. Agri.Sci., B.Sc., PhD
Director
Technical Expertise
Professor James Dale, the lead developer of INPACT, is involved with
Farmacule as its Chief Scientific Officer and as a
major shareholder.
Our company continues to draw on the technical expertise of a group of
biotechnologists who were involved in the initial development of
Farmacule’s core INPACT technology at Queensland University of Technology
(QUT).
An outsourcing arrangement has also been entered into with QUT for scientific
research and further development of INPACT.
Commercialisation & Development
Farmacule is actively pursuing multiple commercial opportunities and its product development activities are geared to the accelerated discovery of innovative technologies and products. Farmacule is assembling the commercialisation skills and resources, both directly and through strategic alliances, to ensure its unique technology exploits all major market opportunities.
Hayley Vandermeer
Business Development Manager
|
